Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 8, 1014

Neuroinflammation, Bone Marrow Stem Cells, and Chronic Pain


Neuroinflammation, Bone Marrow Stem Cells, and Chronic Pain

Yul Huh et al. Front Immunol.


Current treatments for chronic pain, such as inflammatory pain, neuropathic pain, and cancer pain are insufficient and cause severe side effects. Mounting evidence suggests that neuroinflammation in the peripheral and central nervous system (PNS and CNS) plays a pivotal role in the genesis and maintenance of chronic pain. Characteristic features of neuroinflammation in chronic pain conditions include infiltration of immune cells into the PNS [e.g., the sciatic nerve and dorsal root ganglion (DRG)], activation of glial cells such as microglia and astrocytes in the CNS (spinal cord and brain), and production and secretion of pro-inflammatory cytokines and chemokines [TNF, interleukin (IL)-1β, IL-6, CCL2, and CXCL1]. Recent studies suggest that bone marrow stem cells or bone marrow stromal cells (BMSCs) produce powerful analgesic effects in animal models of inflammatory pain, neuropathic pain, and cancer pain. We recently demonstrated that intrathecal injection of BMSCs resulted in a long-term relief of neuropathic pain for several weeks after peripheral nerve injury. Strikingly, this analgesic effect is mediated by the anti-inflammatory cytokine transforming growth factor beta secreted from BMSCs. Additionally, BMSCs exhibit potent modulation of neuroinflammation, by inhibiting monocyte infiltration, glial activation, and cytokine/chemokine production in the DRG and spinal cord. Thus, BMSCs control chronic pain by regulation of neuroinflammation in the PNS and CNS via paracrine signaling. In this review, we discuss the similar results from different laboratories of remarkable anti-nociceptive efficacy of BMSCs in animal and clinical studies. We also discuss the mechanisms by which BMSCs control neuroinflammation and chronic pain and how these cells specifically migrate to damaged tissues.

Keywords: bone marrow stem cells; chronic pain; neuroinflammation; transforming growth factor beta; treatment.


Figure 1
Figure 1
Schematic of bone marrow stromal cell (BMSC) intrathecal injection for treating neuropathic pain. Intrathecal injection introduces bone marrow stromal cells into the cerebrospinal fluid. In mouse models of neuropathic injury of the sciatic nerve, including chronic constriction injury and spared nerve injury, BMSCs expressing CXCR4 specifically migrate to the L4-L6 dorsal root ganglia (DRG) where injured neurons up-regulate the corresponding ligand CXCL12. At the DRG, BMSCs secrete transforming growth factor beta 1, a powerful neuromodulator which rapidly suppresses spinal synaptic plasticity, DRG neuronal hyper-excitability, and neuropathic pain resulting from neuropathic injury. BMSCs that migrate to injured DRGs have been found to survive for 2 months, providing effective, and sustained analgesia.

Similar articles

See all similar articles

Cited by 11 articles

See all "Cited by" articles


    1. Gereau RWT, Sluka KA, Maixner W, Savage SR, Price TJ, Murinson BB, et al. A pain research agenda for the 21st century. J Pain (2014) 15:1203–14.10.1016/j.jpain.2014.09.004 - DOI - PMC - PubMed
    1. Pizzo PA, Clark NM. Alleviating suffering 101—pain relief in the United States. N Engl J Med (2012) 366:197–9.10.1056/NEJMp1109084 - DOI - PubMed
    1. Ji RR, Xu ZZ, Gao YJ. Emerging targets in neuroinflammation-driven chronic pain. Nat Rev Drug Discov (2014) 13:533–48.10.1038/nrd4334 - DOI - PMC - PubMed
    1. Pinho-Ribeiro FA, Verri WA, Jr, Chiu IM. Nociceptor sensory neuron-immune interactions in pain and inflammation. Trends Immunol (2017) 38:5–19.10.1016/ - DOI - PMC - PubMed
    1. Ellis A, Bennett DL. Neuroinflammation and the generation of neuropathic pain. Br J Anaesth (2013) 111:26–37.10.1093/bja/aet128 - DOI - PubMed